<DOC>
	<DOCNO>NCT00810849</DOCNO>
	<brief_summary>Human immunodeficiency virus ( HIV ) infection put people risk opportunistic infection , tuberculosis . In Africa , HIV epidemic result increase number case tuberculosis affect various part body , include membrane surround heart ( i.e. , pericardium ) . Pericardial tuberculosis serious form tuberculosis result death disability 1 2 affected people despite use antituberculosis medication . It suggest addition corticosteroid antituberculosis medication could result reduction number death cause disease , proposal remain confirm appropriately design clinical trial . Similarly , vaccination Mycobacterium w injection also propose possible way reduce damage cause tuberculosis infection heart . The investigator propose conduct clinical trial people antituberculosis treatment pericardial tuberculosis randomly allocate receive either prednisolone matching placebo tablet , Mycobacterium w injection placebo injection . The number people die develop harden pericardium compression heart ( call pericardial constriction ) need emergency evacuation pericardial fluid pericardial sac severe compression ( call tamponade ) compare group determine whether use corticosteroid Mycobacterium w injection safe result reduction death rate . If corticosteroid Mycobacterium w show safely reduce death rate , recommend use patient tuberculosis pericardium future .</brief_summary>
	<brief_title>A Trial Adjunctive Prednisolone Mycobacterium w Immunotherapy Tuberculous Pericarditis</brief_title>
	<detailed_description>Summary research proposal Tuberculous pericarditis one severe form infection Mycobacterium tuberculosis , cause death cardiac disability nearly half affected spite antituberculosis chemotherapy . Attenuation inflammatory response tuberculous pericarditis may improve outcome reduce likelihood cardiac tamponade pericardial constriction . A meta-analysis randomize control trial corticosteroid tuberculous pericarditis show trend towards reduction mortality , study small confirm effect survival . Concern remain corticosteroid might increase frequency opportunistic infection cancer patient infected Human Immunodeficiency Virus ( HIV ) . In addition promise inconclusive evidence adjunctive steroid , preliminary evidence suggest repeat dos Mycobacterium w immunotherapy may reduce inflammation associate extrapulmonary tuberculosis increase CD4 cell count people infect HIV . These early observation remain tested large randomize trial hard endpoint mortality . The Investigation Management Pericarditis Africa ( IMPI [ pronounce 'ee-mp-ee ' , Zulu warrior ] ) Trial ass effectiveness safety oral prednisolone placebo Mycobacterium w immunotherapy placebo 1400 patient tuberculous pericardial effusion . This trial also determine feasibility conduct large-scale multicentre clinical trial patient tuberculous pericarditis sub-Saharan Africa . Hypothesis : We hypothesize patient suspect tuberculous pericarditis randomize adjunctive oral prednisolone 6 week 30 % reduction mortality compare placebo , patient randomize Mycobacterium w injection 6 month good survival compare placebo . Objectives : The primary objective IMPI Trial : ) determine effectiveness oral prednisolone Mycobacterium w immunotherapy reduce composite outcome death , constriction pericardial drainage cardiac tamponade patient tuberculous pericardial effusion , b ) ass safety interactive effect co-administration prednisolone Mycobacterium w immunotherapy , c ) demonstrate feasibility conduct study patient tuberculous pericardial effusion sub-Saharan Africa , establish infrastructure conduct full-scale IMPI trial internal pilot phase first 200 participant . If internal pilot phase positive , patient rolled-over full-scale IMPI trial . The first occurrence death record improve estimate outcomes full-scale trial . Secondary outcomes full-scale trial include : 1 ) constriction , 2 ) rate occurrence cardiac tamponade require pericardiocentesis , 3 ) rate resolution pericardial effusion , 4 ) improvement functional class . Study Design : IMPI randomize double-blind placebo-controlled 2x2 factorial pilot trial enroll 1400 patient multiple centre Kenya , Malawi , Mozambique , Nigeria , Sierra Leone , South Africa , Uganda Zimbabwe . Patients tuberculous pericarditis fulfill inclusion criterion randomly assign receive oral prednisolone placebo 6 week Mycobacterium w injection placebo 6 month . Patients follow closely intervention period ( week 2 , 4 , 6 , month 3 6 ) . Six-monthly follow-up perform thereafter two year . The recruitment 1400 patient perform 54 month , minimum follow-up period 6 month last participant recruit trial . The Population Health Research Institute McMaster University manage coordinate study association IMPI Project Office locate Department Medicine , Groote Schuur Hospital , Cape Town , South Africa .</detailed_description>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Pericarditis</mesh_term>
	<mesh_term>Pericarditis , Tuberculous</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients admit suspected tuberculous pericarditis eligible meet three follow criterion : 1 . A confirmed pericardial effusion echocardiography ; 2 . Evidence definite probable tuberculous pericarditis ; 3 . Within 1 week start antituberculosis treatment . 1 . Presence alternative cause pericardial disease , e.g. , penetrate chest trauma previous 12 month malignancy . 2 . Use corticosteroid within previous month . 3 . Hypersensitivity allergy Mycobacterium w vaccine . 4 . Pregnancy . 5 . Age &lt; 18 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Tuberculosis , pericardium</keyword>
</DOC>